HUP9603370A3 - Nse of rapamycin and derivatives thereof for the preparation of pharmaceutical compositions with neuroprotective activity - Google Patents

Nse of rapamycin and derivatives thereof for the preparation of pharmaceutical compositions with neuroprotective activity

Info

Publication number
HUP9603370A3
HUP9603370A3 HU9603370A HUP9603370A HUP9603370A3 HU P9603370 A3 HUP9603370 A3 HU P9603370A3 HU 9603370 A HU9603370 A HU 9603370A HU P9603370 A HUP9603370 A HU P9603370A HU P9603370 A3 HUP9603370 A3 HU P9603370A3
Authority
HU
Hungary
Prior art keywords
nse
rapamycin
derivatives
preparation
pharmaceutical compositions
Prior art date
Application number
HU9603370A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HU9603370D0 publication Critical patent/HU9603370D0/hu
Publication of HUP9603370A2 publication Critical patent/HUP9603370A2/hu
Publication of HUP9603370A3 publication Critical patent/HUP9603370A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9603370A 1995-12-07 1996-12-06 Nse of rapamycin and derivatives thereof for the preparation of pharmaceutical compositions with neuroprotective activity HUP9603370A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (3)

Publication Number Publication Date
HU9603370D0 HU9603370D0 (en) 1997-01-28
HUP9603370A2 HUP9603370A2 (en) 1997-05-28
HUP9603370A3 true HUP9603370A3 (en) 1998-12-28

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9603370A HUP9603370A3 (en) 1995-12-07 1996-12-06 Nse of rapamycin and derivatives thereof for the preparation of pharmaceutical compositions with neuroprotective activity

Country Status (23)

Country Link
EP (1) EP0778023B1 (hu)
JP (1) JPH09183727A (hu)
KR (1) KR970032856A (hu)
CN (1) CN1112925C (hu)
AR (1) AR008747A1 (hu)
AT (1) ATE234095T1 (hu)
AU (1) AU700653B2 (hu)
BR (1) BR9605895A (hu)
CA (1) CA2192298A1 (hu)
CZ (2) CZ6498A3 (hu)
DE (1) DE69626610T2 (hu)
DK (1) DK0778023T3 (hu)
ES (1) ES2188730T3 (hu)
HU (1) HUP9603370A3 (hu)
IL (1) IL119778A (hu)
MX (1) MX9606131A (hu)
NO (1) NO309966B1 (hu)
NZ (1) NZ299888A (hu)
PT (1) PT778023E (hu)
SI (1) SI0778023T1 (hu)
SK (1) SK154796A3 (hu)
TW (1) TW427904B (hu)
ZA (1) ZA9610245B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
AU2001255406A1 (en) * 2000-04-17 2001-10-30 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
AU2004229567A1 (en) * 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
ES2380779T3 (es) * 2004-12-20 2012-05-18 Wyeth Llc Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios
CN101084226A (zh) 2004-12-20 2007-12-05 惠氏公司 雷帕霉素衍生物及其治疗神经紊乱的用途
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CN104997774A (zh) * 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient COMBINATION THERAPY FOR TAUOPATHIES
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
AU2014276856B2 (en) 2013-06-05 2018-11-15 Pharnext Stable oral solutions for combined API
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
ES2188730T3 (es) 2003-07-01
CZ6498A3 (cs) 1998-06-17
DE69626610T2 (de) 2003-10-02
AU7417896A (en) 1997-06-12
NO309966B1 (no) 2001-04-30
NO965238D0 (no) 1996-12-06
HU9603370D0 (en) 1997-01-28
EP0778023B1 (en) 2003-03-12
EP0778023A1 (en) 1997-06-11
IL119778A0 (en) 1997-03-18
CZ354496A3 (cs) 1998-03-18
PT778023E (pt) 2003-06-30
BR9605895A (pt) 1998-08-18
ATE234095T1 (de) 2003-03-15
MX9606131A (es) 1997-08-30
HUP9603370A2 (en) 1997-05-28
ZA9610245B (en) 1998-06-05
IL119778A (en) 1999-07-14
NZ299888A (en) 2001-02-23
DE69626610D1 (de) 2003-04-17
TW427904B (en) 2001-04-01
AU700653B2 (en) 1999-01-14
SK154796A3 (en) 1997-09-10
KR970032856A (ko) 1997-07-22
SI0778023T1 (en) 2003-08-31
CN1159915A (zh) 1997-09-24
CN1112925C (zh) 2003-07-02
CA2192298A1 (en) 1997-06-08
NO965238L (no) 1997-06-09
JPH09183727A (ja) 1997-07-15
AR008747A1 (es) 2000-02-23
DK0778023T3 (da) 2003-06-30

Similar Documents

Publication Publication Date Title
HUP9603370A2 (en) Nse of rapamycin and derivatives thereof for the preparation of pharmaceutical compositions with neuroprotective activity
IL122212A (en) Rapamycin derivatives, pharmaceutical compositions comprising them and their preparation
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
HUP0000474A3 (en) Arylethenesulfonamide derivatives and drug composition containing the same
NZ238545A (en) Dialkoxy-pyridinyl-benzimidazole derivatives; preparation and pharmaceutical compositions thereof
NZ233320A (en) 3-substituted-2-oxo-indole derivatives and pharmaceutical compositions
HUP0000979A3 (en) Pharmaceutical compositions containing fk-506 and derivatives thereof
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
HUP9802937A3 (en) Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use
HUP9901344A3 (en) Radicicol derivatives and pharmaceutical compositions thereof
IL115905A0 (en) Sordarin derivatives their preparation and pharmaceutical compositions containing them
HUP9802290A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
NZ235270A (en) Diazepinone derivatives and pharmaceutical compositions
HUP9700005A3 (en) 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent
NZ233790A (en) Benzocycloalkane derivatives and pharmaceutical compositions
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
HUP9602196A3 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
AU7275894A (en) Imidazolylalkylamine derivative and pharmaceutical composition thereof
HUP9800631A3 (en) 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
EP0996441A4 (en) PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES
HUP9802291A3 (en) Penicillaminamide derivatives and pharmaceutical compositions containing them
GB9518553D0 (en) New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
NZ239483A (en) Phosphonopyrrolidine or -piperidine derivatives and pharmaceutical compositions